| |
著者: Masako Hara, Tohru Abe, Sachiko Sugawara, Yutaka Mizushima, Keiko Hoshi, Shoichiro Irimajiri, Hiroshi Hashimoto, Shinichi Yoshino, Nobuo Matsui, Masashi Nobunaga, Shigeyuki Nakano
雑誌名: Mod Rheumatol. 2007;17(1):1-9. doi: 10.1007/s10165-006-0542-y. Epub 2007 Feb 20.
Abstract/Text
We conducted a 28-week, randomized, double-blind, parallel-group study of iguratimod in 376 Japanese patients with active rheumatoid arthritis to compare the efficacy and safety of the drug with those of placebo and salazosulfapyridine. In the American College of Rheumatology (ACR) 20 response rate, iguratimod was superior to placebo (53.8% versus 17.2%; Fisher's exact test, P < 0.001) and was not inferior to salazosulfapyridine (63.1% versus 57.7%, 95% confidence interval for the rate difference, -7.9% to 18.7%). Iguratimod began exhibiting its therapeutic effect within 8 weeks after the initiation of treatment and was effective even in patients who had a poor response to previous treatment with disease-modifying antirheumatic drugs. No statistically significant difference was noted in the incidence of adverse reactions between iguratimod and salazosulfapyridine. The study results suggest that iguratimod could become a new option for the treatment of rheumatoid arthritis.
PMID 17278015 Mod Rheumatol. 2007;17(1):1-9. doi: 10.1007/s10165-006-0542-y. Epub 2007 Feb 20.
|
